menu
    • menu
    [{"orgOrder":0,"company":"Themis Bioscience","sponsor":"ABL Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Themis Bioscience \/ Themis Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"Themis Bioscience \/ Themis Bioscience"},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Themis Bioscience \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Themis Bioscience \/ Merck & Co"},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Themis Bioscience \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Themis Bioscience \/ Merck & Co"},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Measles Virus-Chikungunya Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Themis Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Themis Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Virus-drug Conjugate","year":"2016","type":"Inapplicable","leadProduct":"MV-CHIK","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Themis Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Themis Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Walter Reed Army Institute of Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Virus-drug Conjugate","year":"2017","type":"Inapplicable","leadProduct":"MV-CHIK","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Themis Bioscience \/ Walter Reed Army Institute of Research","highestDevelopmentStatusID":"8","companyTruncated":"Themis Bioscience \/ Walter Reed Army Institute of Research"},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Coalition for Epidemic Preparedness Innovations | Harmony Clinical Research | Assign Data Management and Biostatistics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"MV-LASV vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Themis Bioscience \/ Coalition for Epidemic Preparedness Innovations | Harmony Clinical Research | Assign Data Management and Biostatistics","highestDevelopmentStatusID":"6","companyTruncated":"Themis Bioscience \/ Coalition for Epidemic Preparedness Innovations | Harmony Clinical Research | Assign Data Management and Biostatistics"},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRIA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"MV-ZIKA","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Themis Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Themis Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"MV-ZIKA-RSP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Themis Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Themis Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Assign Data Management and Biostatistics | Optimapharm","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"TMV-018","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Themis Bioscience \/ Assign Data Management and Biostatistics | Optimapharm","highestDevelopmentStatusID":"6","companyTruncated":"Themis Bioscience \/ Assign Data Management and Biostatistics | Optimapharm"},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Walter Reed Army Institute of Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"V184","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Themis Bioscience \/ Walter Reed Army Institute of Research","highestDevelopmentStatusID":"8","companyTruncated":"Themis Bioscience \/ Walter Reed Army Institute of Research"},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Themis Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MV-SARS-CoV-2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Themis Bioscience \/ Themis Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Themis Bioscience \/ Themis Bioscience"}]

    Find Clinical Drug Pipeline Developments & Deals by Themis Bioscience

    Menu

    Themis Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SARS-CoV-2 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Merck Completes Acquisition of Themis

                            Details : An initial focus of this agreement is acceleration of the development of a measles vector-based SARS-CoV-2 vaccine candidate. This candidate is currently in pre-clinical development, and clinical studies are planned to start later in 2020.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 19, 2020

                            Lead Product(s) : SARS-CoV-2 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SARS-CoV-2 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Merck to Acquire Themis

                            Details : The planned acquisition builds upon an ongoing collaboration between the two companies to develop vaccine candidates using the measles virus vector platform, and is expected to accelerate the development of Themis’ COVID-19 vaccine candidate.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 26, 2020

                            Lead Product(s) : SARS-CoV-2 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MV-SARS-CoV-2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Institut Pasteur

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mv-Sars-Cov-2 Vaccine Candidate: A New Partnership Between Institut Pasteur, Cepi, Thémis And Msd

                            Details : The development of MV-SARS-CoV-2 is being conducted in partnership with the Austrian biotech company Thémis, which is responsible for the production of preclinical and, clinical batches.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 26, 2020

                            Lead Product(s) : MV-SARS-CoV-2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Institut Pasteur

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : ABL Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Themis Collaborates with ABL Europe to Manufacture its SARS-Cov-2 Vaccine Candidate in France

                            Details : Themis and ABL Europe have signed an agreement under which ABL will manufacture Themis' vaccine candidate in preparation for clinical trials.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 11, 2020

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : ABL Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TMV-018

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Assign Data Management and Biostatistics | Optimapharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract

                            Details : TMV-018 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gastrointestinal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 11, 2019

                            Lead Product(s) : TMV-018

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Assign Data Management and Biostatistics | Optimapharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MV-LASV vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Coalition for Epidemic Preparedness Innovations | Harmony Clinical Research | Assign Data Management and Biostatistics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)

                            Details : MV-LASV vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lassa Fever.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            August 13, 2019

                            Lead Product(s) : MV-LASV vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Coalition for Epidemic Preparedness Innovations | Harmony Clinical Research | Assign Data Management and Biostatistics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MV-ZIKA-RSP Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001)

                            Details : MV-ZIKA-RSP Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Zika Virus Infection.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 25, 2019

                            Lead Product(s) : MV-ZIKA-RSP Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : V184

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Walter Reed Army Institute of Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)

                            Details : V184 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chikungunya Fever.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 17, 2019

                            Lead Product(s) : V184

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Walter Reed Army Institute of Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Measles Virus-Chikungunya Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005...

                            Details : MV-CHIK Vaccine (Measles Virus-Chikungunya Vaccine) is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chikungunya Fever.

                            Product Name : MV-CHIK Vaccine

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            August 17, 2018

                            Lead Product(s) : Measles Virus-Chikungunya Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Themis Bioscience

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MV-CHIK

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Walter Reed Army Institute of Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area

                            Details : MV-CHIK is a Virus-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chikungunya Fever.

                            Product Name : Undisclosed

                            Product Type : Virus-drug Conjugate

                            Upfront Cash : Inapplicable

                            April 04, 2017

                            Lead Product(s) : MV-CHIK

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Walter Reed Army Institute of Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth